Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)

1. Spigel, D.R.
2. Edelman, M.J.
3. O’Byrne, K.
4. Paz-Ares, L.
5. Mocci, S.
6. Phan, S.
7. Shames, D.S.
8. Smith, D.
9. Paton, V.E.
10. Mok, T.